2024 Topics
When submitting an abstract, authors will select one first choice topic and one second choice topic from the list below that best describes their abstract:
A1 – Viral Vectors (excluding AAV – including RNA, adenovirus, herpesvirus, bocavirus, and chimetics)
A2 – AAV Vectors – Virology and Vectorology
A3 – AAV Vectors – Capsid Engineering
A4 – AAV Vectors – Preclinical and Proof-of-Concept In Vivo Studies (Excluding Non-Human Primates)
A5 – AAV Vectors – Non-Human Primates and Large Animal Models
A6 – AAV Vectors – Product Development Manufacturing and Approval Considerations
A7 – AAV Vectors – Immune Modulation
B1 – Metabolic Diseases (including Diabetes)
B2 – Liver Genetic Diseases (including Hemophilia)
B3 – Lysosomal Storage Diseases
B4 – Heart, Lung, and Kidney Diseases
B5 – Neurologic Diseases (Excluding Ophthalmic and Auditory Diseases)
B6 – Ophthalmic and Auditory Diseases
B7 – Musculo-skeletal Diseases
B8 – Genetic Disorders of the Blood and Immune System (Including hemoglobinopathies, hematopoietic lineages, and inherited immune deficiencies such as ADA, X-SCID, and WAS, etc.)
C1 – Base Editing and Prime Editing
C2 – Epigenetic Editing and RNA Editing
C3 – Gene Disruption and Excision
C4 – Targeted Gene Insertion (integrase mediated insertion -targeted or safe harbor)
C5 – On- and Off-Target Method Development
C6 – Gene Targeting and Gene Correction New Technologies
Gene targeting projects focused on specific disease applications are strongly encouraged to submit abstracts to the suitable tissue/disease related category)
D – Oligonucleotide Therapeutics (including siRNAs, aptamers, antagomirs, miRNAs, shRNA, antisense, and splice switching oligos, plasmids)
E1 – Nonviral therapeutic Gene Delivery and Synthetic/Molecular Conjugates
E2 – Other Nonviral Delivery (including lipid nanoparticles and exosomes)
F1 – Cancer – Immunotherapy, Cancer Vaccines
F2 – Cancer – Oncolytic Viruses
F3 – Cancer – Targeted Gene and Cell Therapy
G1 – Challenges in Immunological Responses to Therapeutic Interventions (Includes host responses, therapy/prevention of infectious diseases, nucleic acid therapy, RNA-based Therapies; excludes cancer immunotherapy and cancer vaccines)
G2 – Immune Targeting and Approaches with Genetically-Modified Cells and Cell Therapies (Including CAR-T, CAR-NK, TCR editing)
H1 – Other Cellular and Regenerative Therapies (including Cell and Tissue Transplantation)
H2 – In-Vivo Therapy Approaches
I1 – Vector Product Engineering, Development and Manufacturing (excluding AAV)
I2 – Cell Therapy Product Engineering, Development and Manufacturing
I3 – Pharmacology/Toxicology Studies and Analytics/Assay Development
I4 – Molecular and Cellular Methods (Including assess vector integration, genome integrity, and outcomes)
I5 – Chemistry, Manufacturing, and Controls (excluding Vector & Cell Therapy)
J1 – Gene Therapy Trials – In-Vivo Modification
J2 – Cell Therapy and Cell-Based Gene Therapy Trials
Submit your abstract